In clinical trial analysis, it’s assumed that participants are following the instructions for the investigational product. Unfortunately, the evidence suggests that this is far from reality. Recently, Kenneth Getz, Executive Director and Professor at the Tufts Center for the Study … Read More
Breaking News
Why Objective and Granular Digital Adherence Monitoring is Gaining Traction in Trials.
“Objective and granular” digital adherence measures could improve trial efficiency and allow for better-informed decisions on the efficacy and safety of new drug products. That’s according to the authors of a literature review that looked at more than 100 medicines … Read More
Medication Monitoring Matters Newsletter: February 2023 Edition
Greetings from the forefront of innovation in clinical trials. We’re thrilled to introduce you to the first edition of our medication adherence newsletter, Medication Monitoring Matters. Our focus? Empowering clinical trial sponsors like you to elevate the standard of care … Read More
Medication Technology: Bridging the Gap Between Drug Trials and Real World
With the current push for increased diversity in research, the medical community has accepted the challenge to make trial populations more representative of those in clinical practice. Yet poor medication adherence, which clouds the view of how drugs work in … Read More
AARDEX and Cambridge Cognition Join Forces to Bring Next-Level Adherence Oversight to Hybrid and Decentralized Clinical Trials
Seamless integration of adherence and research data protects participant safety and data quality, with no additional burden for clinical trial sites or participants Liege, Belgium- February 2, 2023: Adherence specialists AARDEX Group and remote research platform experts in the Clinpal team at Cambridge Cognition have teamed up … Read More
Ask the Medication Adherence Experts: Edition One
Poor medication adherence during clinical trials can skew results, leading to underestimations of product efficacy, inaccurate pharmacokinetic/pharmacodynamic calculations, and even put participant safety at risk.1 Research has shown that up to 50% of people who take part in drug development … Read More
Why Near-Perfect Medication Adherence Often Equates to Toxicity.
The World Health Organization (WHO) has recently highlighted how poor adherence can lead to poorer outcomes for prisoners, contributing to health inequalities the world over. But it is worth noting that near-perfect adherence can be just as troublesome within the … Read More
AARDEX Group and medmix Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials
Belgium – medmix Drug Delivery (Haselmeier) and AARDEX Group announced today a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem. Clinical testing during new drug development is costly and time intensive for pharmaceutical and … Read More
Clinical Trials Europe 2022: Learn About Unlocking Medication Adherence Insights to Enhance Drug Development
Poor medication adherence in clinical trials may be a long-standing challenge, but advanced approaches and technologies are finally cutting it down to size. Join AARDEX’s scientific lead at the 21st Clinical Trials Europe event to find out how. Bernard Vrijens and … Read More
Therapeutic Drug Monitoring: The Difference Between Accurate and Reliable
Adherence to medication during clinical trials is a problem of striking magnitude, and one that researchers have employed therapeutic drug monitoring (TDM) to solve for years. But the approach, which measures the level drug or drug metabolites in patients’ blood, … Read More